 |
|
|
| |
In a Placebo Controlled 36 Week Phase 2 Trial, Treatment with MGL-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in NASH on Serial Liver Biopsy
|
| |
| |
Reported by Jules Levin
AASD 2018 Nov 9-13 SF
|
| |
|
|
|
|
|
